Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11773323 | 0.98 | CSNK1D (0.48) | CSNK1DKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL28720076 | 0.83 | IDO1 (0.45) | KDM4ENPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL8700542 | 0.81 | SMN1; SMN2 (0.48) | KDM4ENPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL998243 | 0.80 | IDO1 (0.43) | KDM4ENPC1RAB9AKMT2AIDO1 | |
| SCHEMBL28616856 | 0.80 | IDO1 (0.47) | KDM4ENPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL23108117 | 0.80 | CSNK1D (0.49) | CSNK1DKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL26354914 | 0.78 | IDO1 (0.41) | CSNK1DKDM4ENPC1RAB9AKMT2A | |
| SCHEMBL12381781 | 0.78 | SMN1; SMN2 (0.52) | KDM4ENPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL11961046 | 0.78 | ADORA3 (0.44) | KDM4ENPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL23108232 | 0.77 | GRK6 (0.47) | CSNK1DKDM4ENPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425461-A1 | PREPARATION PROCESS OF INTERMEDIATE, SYNTHESIS PROCESS OF AMINO IMIDAZOLE CARBOXYLATE ESTER AND HPLC PURITY MEASURE METHOD | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2024-12-26 | — | — | US | claimed |
| CN-116789558-A | Preparation method of intermediate, synthesis method of amino imidazole carboxylate and HPLC (high performance liquid chromatography) purity detection method | 深圳艾欣达伟医药科技有限公司 | 2023-09-22 | — | — | CN | claimed |
| US-20240425462-A1 | Preparation Process of 1-N-Methyl-2-Nitro-5-Hydroxymethyl Imidazole | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2024-12-26 | — | — | US | disclosed |
| US-20240425461-A1 | PREPARATION PROCESS OF INTERMEDIATE, SYNTHESIS PROCESS OF AMINO IMIDAZOLE CARBOXYLATE ESTER AND HPLC PURITY MEASURE METHOD | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2024-12-26 | — | — | US | disclosed |
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-10-17 | — | — | US | disclosed |
| US-12115226-B2 | Linker containing arylnitro, antibody-drug conjugate containing linker and use of linker | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2024-10-15 | — | — | US | disclosed |
| WO-2024178127-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20230303618-A1 | TRIPTOLIDE CONJUGATES AND USES THEREOF | REYOUNG CORPORATION (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116803989-A | Preparation process of 1-N-methyl-2-nitro-5-hydroxymethyl imidazole | 深圳艾欣达伟医药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116789558-A | Preparation method of intermediate, synthesis method of amino imidazole carboxylate and HPLC (high performance liquid chromatography) purity detection method | 深圳艾欣达伟医药科技有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-112601556-B | Linker containing aromatic nitro group, antibody conjugate drug containing linker and application of linker | 中国人民解放军军事科学院军事医学研究院 | 2022-08-09 | — | — | CN | disclosed |
| US-7550496-B2 | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1896040-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | Threshold Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007002931-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002931-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-5843942-A | Aromatic amino ethers as pain relieving agents | ZENECA LIMITED (GB) | 1998-12-01 | — | — | US | disclosed |
| EP-0773930-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996003380-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
| US-3987053-A | ANTIMICROBIAL | GRUPPO LEPETIT S.P.A. (IT) | 1976-10-19 | — | — | US | disclosed |
| US-3954789-A | 2-Nitroimidazole derivatives | GRUPPO LEPETIT S.P.A. (IT) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | CSNK1D 673/4885KDM4E 1701/4885NPC1 2461/4885 |
| US-20240425462-A1 | Preparation Process of 1-N-Methyl-2-Nitro-5-Hydroxymethyl Imidazole | DNMT1, COX4I1, NDC1 | CSNK1D 516/4885KDM4E 612/4885NPC1 662/4885 |
| US-20240425461-A1 | PREPARATION PROCESS OF INTERMEDIATE, SYNTHESIS PROCESS OF AMINO IMIDAZOLE CARBOXYLATE ESTER AND HPLC PURITY MEASURE METHOD | ABAT, ALDH7A1, IDH2 | CSNK1D 1582/4885KDM4E 260/4885NPC1 4246/4885 |
| US-12115226-B2 | Linker containing arylnitro, antibody-drug conjugate containing linker and use of linker | BCR, FCGR2A, FCGRT | CSNK1D 2892/4885KDM4E 2409/4885NPC1 1422/4885 |
| US-20230303618-A1 | TRIPTOLIDE CONJUGATES AND USES THEREOF | TLR9, XIAP, ENPP2 | CSNK1D 2640/4885KDM4E 2714/4885NPC1 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.